MD Anderson registers Phase 1a/1b trial combining Jazz's zanidatamab with Boehringer's zongertinib i
A newly listed early-phase study will test the two HER2-targeted drugs together in non-small cell lung cancer, with results not expected before late 2028.
Fact check notes
- Checker's noteThe statement 'a single new trial record accounts for the week's activity' is an unsupported editorial claim not verifiable from the source, though it is a minor framing remark rather than a factual error about the trial itself.
- Sentence removed
A single new trial record accounts for the week's activity.
unsupported: This is an editorial framing statement about the feed's weekly coverage, not something the source document can confirm or deny. - Sentence removed
The study is not yet recruiting, with an estimated start date of April 1, 2027 and estimated primary completion on December 7, 2028, and plans to enroll 24 participants to evaluate safety and tolerability of zongertinib in combination with zanidatamab in patients with HER2-mutant NSCLC, with dose-limiting toxicities in the first 21 days of Part 1 as a co-primary endpoint.
copied source wording
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.